DBV Technologies S.A. (NASDAQ:DBVT) Short Interest Down 5.3% in November

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) saw a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 1,260,000 shares, a drop of 5.3% from the October 31st total of 1,330,000 shares. Approximately 1.3% of the shares of the stock are sold short. Based on an average daily volume of 671,600 shares, the short-interest ratio is presently 1.9 days.

Analyst Ratings Changes

A number of brokerages recently commented on DBVT. JMP Securities reaffirmed a "market outperform" rating and issued a $25.00 target price on shares of DBV Technologies in a research report on Tuesday, September 24th. HC Wainwright upped their price target on shares of DBV Technologies from $25.00 to $35.00 and gave the stock a "buy" rating in a report on Thursday, October 24th. Finally, StockNews.com assumed coverage on DBV Technologies in a research note on Saturday. They issued a "hold" rating on the stock.

DBV Technologies Price Performance

Shares of NASDAQ DBVT traded up $0.28 during midday trading on Tuesday, reaching $4.25. 59,124 shares of the company's stock traded hands, compared to its average volume of 46,183. The stock's 50 day simple moving average is $3.43 and its 200-day simple moving average is $4.15. DBV Technologies has a one year low of $2.20 and a one year high of $10.70.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.